
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/9856/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:07:29 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--9856 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--9856 block--content--website-notice-block block--content--website-notice-block--9856 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--9856 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--9856 block--content--system-main-block block--content--system-main-block--9856 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--9856 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-24-000027.rtf%3b%20filename_%3dUTF-8%27%270001157523-24-000027.rtf" type="application/rtf" title="0001157523-24-000027.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-24-000027.pdf%3b%20filename_%3dUTF-8%27%270001157523-24-000027.pdf" type="application/pdf" title="0001157523-24-000027.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-24-000027.xls%3b%20filename_%3dUTF-8%27%270001157523-24-000027.xls" type="application/vnd.ms-excel" title="0001157523-24-000027.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-24-000027.html" type="application/octet-stream" title="0001157523-24-000027-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:srrk="http://scholarrock.com/20240104" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_519c1ffdba27485a88e3520e6cbdc84c" contextRef="c20240104to20240104" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_efe5e420d7154287a5b43e5435911680" contextRef="c20240104to20240104">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20240104.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20240104to20240104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED








          STATES<br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM








          <ix:nonNumeric name="dei:DocumentType" id="Fact_ac919c498b314a839cf26a693c7fa9d8" contextRef="c20240104to20240104">8-K</ix:nonNumeric></span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT<br />
      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_73d3a257dbd948d4b98e71b398ed1daa" contextRef="c20240104to20240104" format="ixt:date-monthname-day-year-en">January 4, 2024</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_52c7bb01dc1947d9ba1cb8a5b10650e6" contextRef="c20240104to20240104">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_73759dc854f04ca1830eab74da7bdc8c" contextRef="c20240104to20240104" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_73c1a8ad0e1b44c69104a40810d3e553" contextRef="c20240104to20240104">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_18e6fa62985a4211886913a10ea1ce88" contextRef="c20240104to20240104">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_78b04996f6d2415288792c2b076b6904" contextRef="c20240104to20240104">301 Binney Street</ix:nonNumeric><span style="font-weight: bold;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_b9c5234dacff4b27aff443f2f1bdeba5" contextRef="c20240104to20240104">3rd Floor</ix:nonNumeric><span style="font-weight: bold;">, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_fc0c6d5123a2441ca4d5845ee46df77e" contextRef="c20240104to20240104">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_6b26e500290c4b2396162f3ef64aca5a" contextRef="c20240104to20240104">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_48e9eae3543c46bda4e2e689ca3f95ae" contextRef="c20240104to20240104">02142</ix:nonNumeric></span></div>
<div>
        (Address of Principal Executive Offices) (Zip Code)</div>
</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_13764156c873465ab2da3875d2f00aa5" contextRef="c20240104to20240104">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_bba3a81f7b994970a601d1eb7cfd8acf" contextRef="c20240104to20240104">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div>&#160;</div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_1dda876a151044ce9ebd0202fd769143" contextRef="c20240104to20240104" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Written
        communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_d43f513569604af29837ca93cafffbb6" contextRef="c20240104to20240104" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Soliciting
        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_c2db9c0963a5400eb7cd05aaa4d87346" contextRef="c20240104to20240104" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement









        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_2db06ca267e5498dae6000b064cad877" contextRef="c20240104to20240104" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement









        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_8d42fe9fa5354093868085bcae4867cf" contextRef="c20240104to20240104">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_bdeb8c2a51ad46459d8d9e8198f8871e" contextRef="c20240104to20240104">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_129ae73d7ef3496cb09d323f9873e7a0" contextRef="c20240104to20240104" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_4e8b34551f904632bdadc1d7c68555ec" contextRef="c20240104to20240104" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_e31428f8cd704388bb39857e3dae8b17" contextRef="c20240104to20240104" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div><br />
      </div>

      <div>
        <div>
          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 2.02. Results of Operations and Financial Condition.</div>

          <div>&#160;</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On January 4, 2024, Scholar Rock Holding Corporation (the &#8220;Company&#8221;) issued a press release which contained information regarding the
            Company&#8217;s preliminary, unaudited estimate of cash and cash equivalents of approximately $280 million as of December 31, 2023, which is projected to fund the Company&#8217;s operations into the second half of 2025. This information is preliminary and
            unaudited. The Company expects to report its audited cash, cash equivalents and marketable securities, as well as other information necessary for a complete understanding of its financial position, in its Annual Report on Form 10-K for the year
            ended December 31, 2023.</div>

          <div>&#160;</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in this Item 2.02 is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the
            Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section.&#160; It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such
            subsequent filing specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K.</div>

          <div>&#160;</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01. Regulation FD Disclosure.</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
          </div>

          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">On January 4, 2024, the Company announced that management
              will present at the 42</span><sup style="color: #000000;">nd</sup><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 1:30 p.m.
              PT (4:30 p.m. ET).&#160; A copy of the presentation slide deck that will be presented is being furnished as Exhibit 99.1 to this report on Form 8-K.&#160; A live webcast of the presentation may be accessed by visiting the Investors &amp; Media section
              of the Scholar Rock website at </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">http://investors.scholarrock.com</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.</span></div>

          <div>&#160;</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for
            purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section.&#160;&#160;It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent
            filing specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K.</div>

          <div>&#160; <br />
          </div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01. Other Events.</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
          </div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On January 4, 2024, the Company issued a press release announcing a corporate update and highlighting priorities for 2024. A copy of
            this press release is being filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.</div>

          <div>&#160;</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 9.01. Financial Statements and
              Exhibits.</span>&#160;</div>

          <div>&#160;</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

          <div><br />
          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 7%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">No.</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 92%; vertical-align: bottom; text-align: left; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Description</div>
              </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>

    <td style="width: 92%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53878319ex99_1.htm">99.1</a></div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53878319ex99_1.htm">Presentation
                    distributed by Scholar Rock Holding Corporation dated January 8, 2024, furnished hereto.</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53878319ex99_2.htm">99.2</a></div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53878319ex99_2.htm">Press Release issued
                    by Scholar Rock Holding Corporation dated January 4, 2024, filed hereto.</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
              </td>

  </tr>


</table>
        <div>
          <div>&#160;</div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          </div>

        </div>

        <div>
          <div>&#160;</div>

          <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

        </div>

        <div>
          <div>&#160;</div>

          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
            behalf by the undersigned hereunto duly authorized.</div>

          <div><br />
          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.21%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 50.79%; vertical-align: top;" colspan="2">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Scholar Rock Holding Corporation</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.21%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.09%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 47.7%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.21%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.09%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 47.7%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.21%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: January 8, 2024</div>
              </td>

    <td style="width: 3.09%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
              </td>

    <td style="width: 47.7%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Junlin Ho</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.21%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.09%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 47.7%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Junlin Ho</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.21%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.09%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 47.7%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">General Counsel &amp; Corporate Secretary</div>
              </td>

  </tr>


</table>
        <div>
          <div><br />
          </div>

        </div>

      </div>

    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/9856/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:07:29 GMT -->
</html>
</XBRL>
<div><a name="a53878319ex99_1.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<div bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: left;">
    <title></title>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide1.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;&#160;Advancing&#160;&#160;New Possibilities for
            Patients&#160;&#160;42nd ANNUAL J.P. MORGAN&#160;&#160;HEALTHCARE CONFERENCE&#160;&#160;JANUARY 9, 2024&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide2.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;&#169; Scholar Rock, Inc. All rights reserved. 2024.&#160;&#160;Forward-Looking
            Statements&#160;&#160;Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. (&#8220;Scholar Rock&#8221;), including without limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product
            candidate selection and development timing, including timing for the initiation of and reporting results from its preclinical studies and clinical trials for SRK-439, apitegromab, SRK-181, and other product candidates and indication selection
            and development timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary
            platform. The use of words such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to
            identify such forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based on management's current expectations of future
            events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include,
            without limitation, that preclinical and clinical data, including the results from the Phase 2 trial of apitegromab or Part A or Part B of the Phase 1 trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than,
            data generated from future or ongoing clinical trials of the same product candidate, including the Phase 3 clinical trial of apitegromab in SMA and Part B of the Phase 1 clinical trial of SRK-181, respectively, Scholar Rock&#8217;s ability to provide
            the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, information provided
            or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock&#8217;s current
            and potential future collaborations, Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock&#8217;s ability to manage expenses and to
            obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of current macroeconomic and geopolitical events, hostilities in
            Ukraine, increasing rates of inflation and rising interest rates, on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Form 10-K for the year ended
            December 31, 2022, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and
            Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of
            the release, and Scholar Rock undertakes no duty to update this information unless required by law.&#160;&#160;This presentation may also contain estimates and other statistical data made by independent parties and by us relating to market size and
            growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future
            performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk.&#160;&#160;Apitegromab and SRK-181 are investigational drug candidates under evaluation. Apitegromab, SRK-181, and
            SRK-439 have not been approved for any use by the FDA or any other regulatory agency and the safety and efficacy of apitegromab, SRK-181 and SRK-439 have not been established.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide3.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;3&#160;&#160;TGF&#946;=Transforming growth factor-beta. SMA=Spinal muscular atrophy&#160;&#160;*Christopher
            is a participant in the TOPAZ and ONYX clinical trials.&#160;&#160;OUR MISSION&#160;&#160;To discover, develop, and deliver life-changing therapies by harnessing cutting-edge science to create new possibilities for people living with serious diseases&#160;&#160;We are a
            global leader in harnessing the life-changing potential of TGF&#946; biology&#160;&#160;Emily &amp; Christopher&#160;&#160;living with SMA*&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide4.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;4&#160;&#160;Building a Fully Integrated Therapeutics Company&#160;&#160;SMA=Spinal muscular atrophy;
            EMA=European Medicines Agency; FDA=United States Food and Drug Administration; R&amp;D=research and development.&#160;&#160;Apitegromab in SMA&#160;&#160;Potential therapy in Ph 3 designed to improve motor function to help address remaining unmet need after
            receipt of existing SMA therapies&#160;&#160;SRK- 439 in Obesity&#160;&#160;Novel antimyostatin antibody with the potential to support healthier weight management by preserving lean muscle&#160;&#160;SRK-181 in Immuno-Oncology&#160;&#160;In Ph 1 development to overcome resistance to
            checkpoint inhibitors in multiple tumor types&#160;&#160;Revolutionary Scientific Platform&#160;&#160;Pioneers in unparalleled&#160;&#160;selective targeting of the latent forms&#160;&#160;of growth factors&#160;&#160;Robust pipeline of novel assets including two clinical programs and a
            growing portfolio of preclinical programs&#160;&#160;Transformative Therapeutics&#160;&#160;in Development&#160;&#160;Experienced and Focused&#160;&#160;Seasoned team with track record of&#160;&#160;clinical and commercial success&#160;&#160;Deep rare disease, R&amp;D, FDA/EMA&#160;&#160;approval &amp; launch
            experience&#160;&#160;Focused, efficient approach to scaling the organization&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide5.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Traditional Target&#160;&#160;&#8220;mature&#8221; active growth factor&#160;&#160;Scholar Rock&#8217;s Target&#160;&#160;Latent
            Growth Factor&#160;&#160;Our Approach&#160;&#160;S e l e c t i v i t y D r i v e s S u c c e s s&#160;&#160;Industry-leading antibody design and protein engineering to selectively target latent growth factors&#160;&#160;Optimized for efficacy and mitigates off-target effects&#160;&#160;Deep
            structural insights to validated targets&#160;&#160;RIGHT&#160;&#160;TIME&#160;&#160;L a t e n t&#160;&#160;F o r m&#160;&#160;RIGHT&#160;&#160;TARGE T&#160;&#160;V a l i d a t e d B i o l o g y&#160;&#160;5&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide6.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Latent&#160;&#160;Myostatin&#160;&#160;SPINAL MUSCULAR ATROPHY&#160;&#160;Apitegromab&#160;&#160;CARDIOMETABOLIC
            DISORDERS&#160;&#160;Apitegromab in Obesity*&#160;&#160;SRK-439 (novel antimyostatin antibody)&#160;&#160;Latent&#160;&#160;TGF&#946;-1&#160;&#160;IMMUNO-ONCOLOGY&#160;&#160;SRK-181 (selective context-independent,&#160;&#160;anti-latent TGF&#946;-1)&#160;&#160;FIBROSIS&#160;&#160;Selective context-dependent (LTBP1 &amp; LTBP3) anti-latent
            TGF&#946;-1&#160;&#160;RGMc&#160;&#160;ANEMIA&#160;&#160;Selective anti-RGMc&#160;&#160;TARGET&#160;&#160;DISCOVERY/&#160;&#160;PRECLINICAL PHASE 1 PHASE 2 PHASE 3&#160;&#160;Potential to transform the lives of people living with a wide range of serious diseases, including neuromuscular disorders, cardiometabolic
            disorders, oncology, and fibrosis&#160;&#160;Advancing a Robust Pipeline with Our Differentiated Platform&#160;&#160;* Subject to receipt of regulatory authority approval. We plan to utilize data from a previously completed Ph 1 study in healthy volunteers and
            initiate a Ph 2 POC trial in 2024.&#160;&#160;LTBP1=Latent transforming growth factor beta binding protein 1; LTBP3=Latent transforming growth factor beta binding protein 3; POC=Proof of concept; RGMc=Repulsive guidance molecule C; TGF&#946;-1=Transforming
            growth factor beta-1.&#160;&#160;6&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide7.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;&#160;Antimyostatin Program: Apitegromab
            in Spinal Muscular Atrophy&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide8.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;8&#160;&#160;Hallmarks of SMA&#160;&#160;Motor Neuron Loss and Muscle Atrophy Leads to Progressive
            Muscle Weakness&#160;&#160;SMA=Spinal muscular atrophy; SMN=Survival motor neuron.&#160;&#160;Hua Y, et al. Nature. 2011;478(7367):123-6.&#160;&#160;Figure adapted from: SMA Foundation Overview. http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf.;
            Accessed April 18, 2021.&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;SMN therapies&#160;&#160;slow further degeneration of motor neurons1&#160;&#160;...but do not directly address muscle atrophy&#160;&#160;Motor neuron degeneration2&#160;&#160;Muscle fiber&#160;&#160;atrophy&#160;&#160;Spinal Muscular
            Atrophy&#160;&#160;Motor neuron impairment and loss due to SMN genetic deficiency leads to muscle atrophy and weakness&#160;&#160;There is further potential to&#160;&#160;regain vital muscle function by also addressing the progressive muscle atrophy and associated weakness
            of SMA&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide9.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SMA Leads to Deterioration in Essential Muscle Function&#160;&#160;Quotes are from patient
            advocates who participated in 2022 Cure SMA FDA Patient-Led Listening Session and not from the pictured individuals. Summary of the listening session can be found on the FDA website at
            https://www.curesma.org/cure-sma-holds-patient-led-listening-session-with-fda/&#160;&#160;9&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;Despite significant advancements, progressive muscle weakness remains an unmet need in SMA&#160;&#160;Small tasks are huge
            success in my life. If I could lift that 1L bottle of water at work instead of having to find a graduate student to move it for me&#8230;things don&#8217;t take a ton more muscle, but they are all muscle I still don&#8217;t have.&#160;&#160;What may seem like minimal
            gains in strength actually translate to exponential gains in functional abilities.&#160;&#160;I often have to choose between taking a shower and doing homework because I don't have the energy to do both.&#160;&#160;Muscle weakness can lead to deterioration in
            mobility, swallowing, breathing and cause debilitating fatigue&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide10.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;10&#160;&#160;SMA Today: More Patients Screened and Treated&#160;&#160;CHF=Swiss franc; LTM=last
            twelve months; SMA=Spinal muscular atrophy; SMN=Survival motor neuron; WW=worldwide.&#160;&#160;Cure SMA 2022 Report: 9042022_State-of-SMA_vweb.pdf (curesma.org)&#160;&#160;Lally et al. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II,
            and III in the United States. Orphanet J Rare Dis. 2017 Nov 28;12(1):175. doi: 10.1186/s13023-017-0724-z.&#160;&#160;Revenue as of Biogen 3Q23 financial update; includes patients treated worldwide in post-marketing setting, expanded access program, and
            clinical trials as of May 2022.&#160;&#160;Revenue as of Roche 3Q23 financial update; includes patients treated worldwide as of July 2023.&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;GLOBAL DISEASE:&#160;&#160;&gt;20,000 affected&#160;&#160;in US and Europe1, 2&#160;&#160;Three
            treatments to address SMN loss&#160;&#160;&gt;13,000 patients&#160;&#160;treated WW&#160;&#160;$1.8 billion&#160;&#160;annual revenue (LTM)3&#160;&#160;&gt; 11,000 patients&#160;&#160;treated WW&#160;&#160;~CHF1.4 billion&#160;&#160;annual revenue (LTM)4&#160;&#160;&gt; 3,500 patients&#160;&#160;treated WW&#160;&#160;~$1.2 billion&#160;&#160;in revenues
            (LTM)5&#160;&#160;Established market dynamics support Scholar Rock&#8217;s first potential commercial launch&#160;&#160;5. Revenue as of Novartis 3Q23 financial update; includes patients treated worldwide including clinical trials, commercially, and managed access
            programs as of August 2023.&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide11.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;11&#160;&#160;Muscle-Targeted Therapy: A New Treatment Frontier&#160;&#160;*Percentages represent
            percent of patients who named these unmet needs when asked, &#8220;What are your most significant current unmet needs that you hope new therapies would address?&#8221;&#160;&#160;HFMSE=Hammersmith Functional Motor Scale-Expanded.&#160;&#160;1. Mercuri E et al.; N Engl J Med
            2018; 378:625-635; DOI: 10.1056/NEJMoa1710504; cherish trial results; 2. 2022 Community Update Survey, Cure SMA.&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;0&#160;&#160;Mean improvement in HFMSE experienced by patients in nusinersen Phase 3 CHERISH
            trial1&#160;&#160;20&#160;&#160;40&#160;&#160;60&#160;&#160;80&#160;&#160;3.9-point increase&#160;&#160;in HFMSE from nusinersen&#160;&#160;(4.9 point increase relative to sham control)&#160;&#160;HFMSE Score at Month 15&#160;&#160;Total Possible&#160;&#160;HFMSE Score of 66&#160;&#160;Unmet need remains substantial&#160;&#160;Patients and caregivers want new
            therapies to address the following unmet needs2 :&#160;&#160;INCREASE&#160;&#160;muscle strength&#160;&#160;This third-party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.&#160;&#160;&#169; 2024 Scholar
            Rock, Inc. All rights reserved.&#160;&#160;IMPROVE&#160;&#160;daily activities&#160;&#160;STABILIZE&#160;&#160;or GAIN new motor function&#160;&#160;REDUCE&#160;&#160;fatigue&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide12.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;12&#160;&#160;Apitegromab Offers Significant Potential to Address Unmet Needs&#160;&#160;* Based on
            Animal Model Data; 1. Long KK, et al. Hum Mol Genet. 2019;28(7):1077-1088; 2. Pirruccello-Straub M, et al. Sci Reports. 2018;8(1):2292. doi:10.1038/s41598-018-20524-9 3.&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;Apitegromab is a selective
            MUSCLE-TARGETED APPROACH&#160;&#160;designed to improve motor function*1,2&#160;&#160;Myostatin is a negative modulator of muscle growth&#160;&#160;Strong clinical and preclinical evidence indicates upstream targeting of structurally differentiated pro- and latent myostatin
            avoids undesirable off-target effects&#160;&#160;Apitegromab specifically and only inhibits myostatin and has the potential to build muscle and strength&#160;&#160;to improve patient outcomes&#160;&#160;Apitegromab&#160;&#160;Muscle fiber&#160;&#160;atrophy&#160;&#160;Motor neuron&#160;&#160;degeneration3&#160;&#160;Figure
            adapted from: SMA Foundation Overview. http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf.; Accessed April 18, 2021. For illustrative purposes only.&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide13.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;&#160;Time (weeks)&#160;&#160;No. of
            observations&#160;&#160;N = 35; Baseline mean age=7.3 |Time on SMN Rx=24.1m&#160;&#160;PRO=patient reported outcomes; HFMSE=Hammersmith Functional Motor Scale Expanded; OC=observed case; PEDI-CAT=Pediatric Evaluation of Disability Inventory Computer Adaptive Test;
            PROMIS=Patient Reported Outcome Measurement Information System; RULM=Revised upper limb module; SE=standard error of the mean. Pooled nonambulatory patients, age 2-21, all doses. Crawford et al., Cure SMA 2023&#160;&#160;32&#160;&#160;32 31&#160;&#160;27&#160;&#160;27&#160;&#160;27&#160;&#160;Change
            from baseline (&#177;SE)&#160;&#160;Year 1&#160;&#160;IMPROVEMENT&#160;&#160;8&#160;&#160;7&#160;&#160;6&#160;&#160;5&#160;&#160;4&#160;&#160;3&#160;&#160;2&#160;&#160;1&#160;&#160;0&#160;&#160;-1&#160;&#160;-2&#160;&#160;0&#160;&#160;136&#160;&#160;156&#160;&#160;Year 1&#160;&#160;IMPROVEMENT&#160;&#160;2&#160;&#160;1&#160;&#160;0&#160;&#160;-1&#160;&#160;-2&#160;&#160;-3&#160;&#160;-4&#160;&#160;-5&#160;&#160;-6&#160;&#160;-7&#160;&#160;-8&#160;&#160;0&#160;&#160;PROMIS Fatigue (Proxy)&#160;&#160;Year 2 Year 3&#160;&#160;IMPROVEMENT&#160;&#160;28&#160;&#160;27&#160;&#160;Change from baseline
            (&#177;SE)&#160;&#160;5&#160;&#160;4&#160;&#160;3&#160;&#160;2&#160;&#160;1&#160;&#160;0&#160;&#160;-1&#160;&#160;-2&#160;&#160;0&#160;&#160;Time (weeks) 0 8 16 24 32 40 52 68 84 104 120 136 156 0 8 16 24 32 40 52 68 84 104 120 136 156&#160;&#160;No. of observations 31 29 30 21 23 25 25 27 22 23 16 15 17 25 23 22 19 19 22 16 18 19 19 16 14 14&#160;&#160;0 8 16 24 32
            40 52 68 84 104 120&#160;&#160;35 35 34 29 28 29 32 32 32 29 27&#160;&#160;PEDI-CAT Daily Activities&#160;&#160;Year 1 Year 2 Year 3&#160;&#160;Year 3&#160;&#160;Year 2 Year 3 Year 1 Year 2&#160;&#160;-2&#160;&#160;-1&#160;&#160;0&#160;&#160;1&#160;&#160;2&#160;&#160;3&#160;&#160;4&#160;&#160;0&#160;&#160;0 8 16 24 32 40 52&#160;&#160;34 34 34 28 27 29 31&#160;&#160;68&#160;&#160;84
            104&#160;&#160;120&#160;&#160;136&#160;&#160;156&#160;&#160;IMPROVEMENT&#160;&#160;HFMSE RULM&#160;&#160;13&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;TOPAZ Over 36 Months&#160;&#160;Sustained Functional and PRO Improvements Beyond SMN Treatment&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide14.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;14&#160;&#160;TOPAZ Over 36 Months&#160;&#160;Well Tolerated Safety Profile &amp; Low Discontinuation
            Rate&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;RIGHT TIME&#160;&#160;L a t e n t F o r m&#160;&#160;M y o s t a t i n&#160;&#160;RIGHT&#160;&#160;TARGE T&#160;&#160;Crawford et al., Cure SMA 2023&#160;&#160;* Excludes patients on monotherapy&#160;&#160;&gt;90% of patients on combination therapy remained in
            extension&#160;&#160;study*&#160;&#160;Treatment-emergent adverse events (TEAEs) were consistent with previous reports with no new findings after 198 patient- years of exposure&#160;&#160;&#8211; Most frequently reported TEAEs included headache, pyrexia,&#160;&#160;COVID-19,
            nasopharyngitis, &amp; upper respiratory tract infection&#160;&#160;&#8211; TEAEs were mostly mild to moderate and generally consistent with the underlying patient population and nusinersen therapy&#160;&#160;No treatment-related serious AEs or hypersensitivity
            reactions&#160;&#160;No report of positive apitegromab antibodies (ADA)&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide15.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;15&#160;&#160;SAPPHIRE Phase 3 Design is Optimized by Insights from TOPAZ&#160;&#160;HFMSE=Hammersmith
            Functional Motor Scale Expanded.&#160;&#160;TOPAZ Learnings&#160;&#160;SAPPHIRE Design Elements&#160;&#160;Phase 3 SAPPHIRE Trial Registrational trial with topline 12-month data readout expected in Q4 2024&#160;&#160;S T U D Y P O P U L A T I O N&#160;&#160;Substantial HFMSE gains observed in
            the nonambulatory Type 2/3 SMA cohorts&#160;&#160;A G E&#160;&#160;Exploratory age 2-12 analysis in nonambulatory&#160;&#160;Type 2/3 showed transformative potential&#160;&#160;D U R A T I O N&#160;&#160;HFMSE gains substantial by 12 months of treatment&#160;&#160;D O S E&#160;&#160;Dose response seen (greater
            effect observed with 20 mg/kg over 2 mg/kg)&#160;&#160;S T U D Y P O P U L A T I O N&#160;&#160;Nonambulatory Type 2/3 SMA&#160;&#160;Primary efficacy endpoint: HFMSE&#160;&#160;A G E&#160;&#160;Age 2-12 main efficacy population&#160;&#160;Age 13-21 exploratory population&#160;&#160;D U R A T I O N&#160;&#160;12-month
            treatment duration&#160;&#160;D O S E&#160;&#160;20 mg/kg apitegromab dose&#160;&#160;10 mg/kg apitegromab dose&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide16.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;16&#160;&#160;Apitegromab: Potential to Maximize Outcomes for People Living with Spinal
            Muscular Atrophy (SMA)&#160;&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy (SMA). Apitegromab has not been approved for any use by the FDA or any other regulatory agency, and its safety
            and efficacy have not been established.&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;Phase 2 TOPAZ Trial Demonstrated substantial and sustained functional improvements in Type 2 and nonambulatory Type 3 SMA patients&#160;&#160;First and only
            muscle-targeted investigational treatment&#160;&#160;to demonstrate clinical proof-of-concept in SMA&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;&#160;Phase 3 SAPPHIRE Trial&#160;&#160;Registrational trial with topline 12-month data expected in Q4 2024&#160;&#160;ONYX
            Open-Label&#160;&#160;Extension Study&#160;&#160;Evaluating the long-term safety and efficacy of apitegromab in patients who have completed TOPAZ or SAPPHIRE&#160;&#160;Transformative Potential to Change the Standard of Care&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide17.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;17&#160;&#160;Expanding to Benefit More People Living with SMA&#160;&#160;*Subject to regulatory
            approval.&#160;&#160;SMA=Spinal muscular atrophy; Sub-Q=Subcutaneous&#160;&#160;S P I N A L M U S C U L A R A T R O P H Y&#160;&#160;WHERE WE ARE&#160;&#160;WHERE WE WERE&#160;&#160;WHERE WE ARE GOING&#160;&#160;P H A S E 2&#160;&#160;12-Month&#160;&#160;COMPLETE&#160;&#160;24-Month EXTENSION COMPLETE&#160;&#160;36-Month EXTENSION
            COMPLETE&#160;&#160;12-Month&#160;&#160;Q4 2024&#160;&#160;data&#160;&#160;P H A S E 3&#160;&#160;Scale for Commercial Launch (2025)*&#160;&#160;Under 2 Years of Age&#160;&#160;(including those treated with gene therapy)&#160;&#160;Ambulatory Population&#160;&#160;Sub-Q Formulation&#160;&#160;Long-term&#160;&#160;EXTENSION for&#160;&#160;TOPAZ and SAPPHIRE
            studies&#160;&#160;C O M M E R C I A L I Z A T I O N&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide18.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;&#160;Next Horizon&#160;&#160;Antimyostatin
            Program: Cardiometabolic Disorders&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide19.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Obesity is Recognized as a Top Global Public Health Issue&#160;&#160;1. The World Obesity
            Foundation, World Obesity Atlas 2022; 2. Ward ZJ, Bleich SN, Long MW, Gortmaker SL (2021) Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE 16(3): e0247307.&#160;&#160;BY 2030, OBESITY WILL
            AFFECT:&#160;&#160;&gt;1 BILLION&#160;&#160;adults&#160;&#160;&gt;250 MILLION&#160;&#160;children and&#160;&#160;adolescents1&#160;&#160;Obesity can increase&#160;&#160;the risk of comorbidities, such as some cancers, heart disease, and&#160;&#160;type 2 diabetes&#160;&#160;Adult obesity associated with more than $170 billion&#160;&#160;in
            excess costs&#160;&#160;annually in the U.S.2&#160;&#160;In the US,&#160;&#160;1 in 5 children and&#160;&#160;more than 1 in 3&#160;&#160;adults are obese&#160;&#160;Obesity is a common, serious, and costly chronic disease affecting adults and children worldwide&#160;&#160;19&#160;&#160;O B E S I T Y&#160;&#160;&#169; 2024 Scholar Rock,
            Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide20.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;20&#160;&#160;Loss of Lean Muscle Significant with GLP-1 RA Therapy&#160;&#160;Lean muscle is
            essential to healthy metabolic function&#160;&#160;GLP-1 RA=Glucagon-like peptide-1 receptor agonists.&#160;&#160;1. Muller TD, et al Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022; 21, 201&#8211;223; 2. Wilding JPH, Batterham
            RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002; 3. Jastreboff AM, et al Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022; 387 (3): 205-216; 4. Cava et al.
            Preserving healthy muscle during weight loss. Adv Nutr 2017;8:511-19; 5. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide or Both Combined. NEJM 2021;384:1719-30;&#160;&#160;6. Beal JW et al. Dietary weight loss-induced
            improvements in metabolic function are enhanced by exercise in people with obesity and prediabetes. Nat Metab. 2022;5(7):1221-1235; 7. Dulloo AG, et al How dieting makes some fatter: from a perspective of human body composition autoregulation.
            Proc Nutr Soc. 2012 Aug;71(3):379-89.&#160;&#160;O B E S I T Y&#160;&#160;Significant proportion of weight loss due to loss of lean muscle mass&#160;&#160; &#160;&#160;Recently approved GLP-1 RAs are highly effective in weight loss &amp; experiencing rapid uptake&#160;&#160;But 25%-40% of
            total body weight loss mediated by GLP-1 RA therapy may be attributed to loss of lean muscle mass2,3&#160;&#160;Preserving lean muscle mass is important to promote&#160;&#160;long-term metabolic benefits, sustainable weight management and health
            outcomes4-7&#160;&#160;Current Weight Loss Strategies Challenged by:&#160;&#160;Tolerability&#160;&#160;Lack of durability&#160;&#160;Significant&#160;&#160;muscle loss1-3&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide21.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;21&#160;&#160;Maintaining Muscle is Important for Healthy Weight Loss&#160;&#160;GLP-1
            RA=Glucagon-like peptide-1 receptor agonist.&#160;&#160;1. Aristizabal JC, Freidenreich DJ, Volk BM, et al. Effect of resistance training on resting metabolic rate and its estimation by a dual-energy X-ray absorptiometry metabolic map. Eur J Clin
            Nutr.2015; 69, 831&#8211;836. https://doi.org/10.1038/ejcn.2014.216; 2. Lindegaard B, Hansen T, Hvid T, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients
            with lipodystrophy. J Clin Endocrinol Metab. 2008; 93:3860&#8211;9; 3. Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition
            Examination Survey. J Clin Endocrinol Metab. 2011; 96:2898&#8211;903. doi: 10.1210/jc.2011-0435; 4. Wewege MA, Desai I, Honey C, et al. The effect of resistance training in healthy adults on Body fat percentage, fat mass and visceral fat: A
            systematic review and meta-analysis. Sports Med. 2022(Feb);52(2):287-300. doi: 10.1007/s40279-021-01562-2; 5. Zurlo, F., Larson, K., Bogardus, C., et al. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin
            Invest. 1990;86(5), 1423-1427; 6. Fukushima Y, Kurose S, Shinno H, et al. Importance of lean muscle maintenance to improve insulin resistance by body weight reduction in female patients with obesity. Diabetes Metab J. 2016;40: 147-153; 7. Roh
            E, Choi KM. Health consequences&#160;&#160;The preservation of lean mass has many benefits for overall health:&#160;&#160;Improved strength&#160;&#160;Improved insulin sensitivity&#160;&#160;Increased basal metabolic rate&#160;&#160;Improved metabolic profile&#160;&#160;Reduced total body fat&#160;&#160;O B E S I
            T Y&#160;&#160;Better insulin sensitivity&#160;&#160;and lower risk of prediabetes3&#160;&#160;Reduced visceral fat4&#160;&#160;Increased bone density, strength, function, and longevity and decreased risk of injury, and disability6-8&#160;&#160;Increased caloric expenditure
            post-exercise5&#160;&#160;Enhanced glucose homeostasis2&#160;&#160;Increased basal metabolic rate (BMR)1&#160;&#160;of sarcopenic obesity: a narrative review. Front. Endocrinol. 2020;11: 332; 8. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin
            Nutr Metab Care. 2004;7(4): 405-410.&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide22.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;22&#160;&#160;Our Antibodies Selectively Inhibit Activation of Myostatin&#160;&#160;ActRIIB=Activin
            Receptor IIB; FSH=Follicle stimulating hormone; GDF-11=Growth and differentiation factor 11; TGF-&#946;=Transforming growth factor-beta.&#160;&#160;1. Oh SP &amp; Li E. Genes Dev. 1997 Jul 15;11(14):1812-26; 2. Garito T, et al. Clin Endocrinol (Oxf). 2018
            Jun;88(6):908-919; 3. McPherron AC et al Nat Genet 1999, 22(3):260-264.; 4. Joonho Suha et al&#160;&#160;O B E S I T Y&#160;&#160;ActRIIB&#160;&#160;Myostatin&#160;&#160;Activin A&#160;&#160;GDF-11&#160;&#160;Selective Targeting of Proforms of Myostatin&#160;&#160;Promyostatin Pro-GDF-11 Proactivin&#160;&#160;SRRK
            antibodies do not bind to mature myostatin or any form of GDF11, Activin A, or other TGF-&#946; family members&#160;&#160;Selectivity is critical to avoid&#160;&#160;safety concerns&#160;&#160;Apitegromab&#160;&#160;and&#160;&#160;SRK-439&#160;&#160;LATENT FORMS&#160;&#160;MATURE FORMS&#160;&#160;Broad inhibition of ActRIIb
            signaling may be problematic:&#160;&#160;ActRIIB knockout animals die shortly after birth with developmental defects in respiratory and cardiac organs1&#160;&#160;Activins are critical in reproductive biology, and inhibition was shown to reduce FSH levels in
            women2&#160;&#160;GDF11 loss leads to embryonic lethality, skeletal and kidney formation defects3&#160;&#160;GDF11 signaling inhibition may have negative impacts on bone4, 5&#160;&#160;Proc Natl Acad Sci U S A . 2020 Mar 3;117(9):4910-4920; 5, Ravenscroft TA et al. Genet
            Med 2021 Oct;23 (10):1889-1900).&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide23.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;23&#160;&#160;SRK-439: Novel Myostatin Inhibitor&#160;&#160;Preclinical candidate in development with
            potential to address muscle loss associated with weight loss&#160;&#160;mTLL2 IC50: Inhibitory concentration at 50% as measure of in vitro potency of the antibody in its ability to inhibit the activation of latent myostatin by its activating enzyme
            mammalian tolloid like protease 2 | KD: Equilibrium dissociation constant as a measure of binding affinity of the antibody to latent myostatin.&#160;&#160;O B E S I T Y&#160;&#160;SRK-439&#160;&#160;Promyostatin&#160;&#160;Myostatin&#160;&#160;Attractive Properties&#160;&#160;High in vitro affinity&#160;&#160;for
            pro- and&#160;&#160;latent myostatin&#160;&#160;Optimized for subcutaneous formulation and dosing&#160;&#160;Maintained myostatin specificity (No GDF-11 or&#160;&#160;Activin-A binding)&#160;&#160;Maintained&#160;&#160;good developability&#160;&#160;profile&#160;&#160;GDF-11=Growth and differentiation factor 11.&#160;&#160;&#169; 2024
            Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide24.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;24&#160;&#160;SRK-439 Reversed Lean Mass Loss and&#160;&#160;Enhanced Fat Mass Loss Induced by
            Semaglutide Treatment&#8224;&#160;&#160;&#8224; In Mouse Diet Induced Obesity (DIO) Model.&#160;&#160;Figure showed the effects of increasing doses of SRK-439 in combination with semaglutide on lean mass (left panel) and fat mass (right panel) in DIO mouse model as measured
            by qNMR; statistical analysis was done using one-way ANOVA (Dunnett&#8217;s multiple comparison test).&#160;&#160;O B E S I T Y&#160;&#160;-20&#160;&#160;-10&#160;&#160;0&#160;&#160;10&#160;&#160;20&#160;&#160;Additional Fat Mass Loss vs Semaglutide Alone&#160;&#160;Dose-dependent Preservation of Lean Mass with effects seen as
            low as 0.3mg/kg&#160;&#160;One-way ANOVA&#160;&#160;* P &lt; 0.05&#160;&#160;** P &lt; 0.005&#160;&#160;*** P &lt; 0.0005&#160;&#160;**** P &lt; 0.0001&#160;&#160;% Change &#8211; Fat Mass (qNMR)&#160;&#160;% Change &#8211; Lean Mass (qNMR)&#160;&#160;% Change&#160;&#160;*&#160;&#160;****&#160;&#160;0.1&#160;&#160;3.0&#160;&#160;IgG&#160;&#160;Semaglutide 0.04 mg/kg&#160;&#160;SRK-439 IgG&#160;&#160;0.3
            1.0&#160;&#160;SRK-439 (mg/kg)&#160;&#160;SRK-439&#160;&#160;0.06 mg/kg Lira&#160;&#160;-80&#160;&#160;-60&#160;&#160;-40&#160;&#160;-20&#160;&#160;0&#160;&#160;20&#160;&#160;% Change&#160;&#160;Semaglutide 0.04 mg/kg&#160;&#160;0.1&#160;&#160;3.0&#160;&#160;SRK-439&#160;&#160;IgG&#160;&#160;IgG&#160;&#160;0.3 1.0&#160;&#160;SRK-439 (mg/kg)&#160;&#160;ANOVA=Analysis of variance; IgG=Immunoglobulin G; qNMR=Quantitative nuclear
            magnetic resonance.&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide25.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;25&#160;&#160;Opportunity for Safe, Durable Weight Loss: Add Highly Selective Antimyostatin
            to GLP-1 RA to Preserve Lean Muscle&#160;&#160;GLP-1 RA=Glucagon-like peptide-1 receptor agonist.&#160;&#160;1. Pirruccello-Straub M et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Reports 2017;8:2922; 2. Welsh
            BT et al. Preclinical safety assessment and toxicokinetics of apitegromab, an antibody targeting proforms of myostatin for the treatment of muscle-atrophying disease. Int J Tox 2021;40(4):322-336; 3. Barrett D et al. A randomized phase 1
            safety, pharmacokinetic and pharmacodynamic study of a novel myostatin inhibitor apitegromab (SRK-015): A potential treatment for spinal muscular atrophy. Adv Ther 2021;38:3203-3222. 4.Yang&#160;&#160;O B E S I T Y&#160;&#160;Myostatin Inhibition&#160;&#160;Preclinical
            models demonstrated: increased muscle mass&#160;&#160;Beneficial metabolic effects&#160;&#160;(insulin sensitivity, basal metabolic&#160;&#160;rate, reduction in fat mass)4&#160;&#160;Exquisite Selectivity&#160;&#160;Only inhibits myostatin&#160;&#160;Avoids undesirable off-target&#160;&#160;effects 1-3&#160;&#160;Lean
            Muscle Retention&#160;&#160;Inhibition of myostatin in combination with GLP-1 RA-driven weight loss may lead to retention of lean muscle mass and combat the counter-regulatory metabolic effects of weight loss&#160;&#160;M et al. Myostatin: A potential therapeutic
            target for metabolic syndrome. Frontiers in Endocrinology 2023;14:1181913;&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide26.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;26&#160;&#160;Expedite Cardiometabolic Program with&#160;&#160;Ph2 Proof-of-Concept Study of
            Apitegromab in Obesity&#160;&#160;* Anticipated milestones.&#160;&#160;Creates additional anticipated milestones in next 18-24 months&#160;&#160;O B E S I T Y&#160;&#160;2024&#160;&#160;2025&#160;&#160;Spinal Muscular Atrophy&#160;&#160;Apitegromab&#160;&#160;SAPPHIRE&#160;&#160;Topline Q4*&#160;&#160;Potential Commercial
            Launch*&#160;&#160;Cardiometabolic Disorders&#160;&#160;POC study start*&#160;&#160;POC data readout*&#160;&#160;Apitegromab POC&#160;&#160;APITEGROMAB + GLP-1 RA&#160;&#160;Ph 2 proof-concept-trial&#160;&#160;IND*&#160;&#160;SRK-439&#160;&#160;SRK-439 + GLP-1 RA&#160;&#160;Novel asset for&#160;&#160;cardiometabolic indication&#160;&#160;GLP-1 RA=Glucagon-like
            peptide-1 receptor agonist; IND=Investigational new drug; POC=Proof of concept.&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide27.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Building on this success,&#160;&#160;in 2024&#160;&#160;we are focused on&#160;&#160;27&#160;&#160;Key Accomplishments and
            2024 Strategic Priorities&#160;&#160;2023&#160;&#160;ACCOMPLISHMENTS&#160;&#160;COMPLETED&#160;&#160;SAPPHIRE enrollment&#160;&#160;EXPANDED&#160;&#160;antimyostatin program into cardiometabolic disorders&#160;&#160;SUCCESSFUL&#160;&#160;$98M public offering, extending projected runway into second half of
            2025&#160;&#160;SAPPHIRE&#160;&#160;Readout in Q4&#160;&#160;Initiate Ph 2 POC trial with apitegromab in obesity&#160;&#160;Advance&#160;&#160;IND-enabling studies for SRK-439&#160;&#160;Prepare for commercialization&#160;&#160;IND=Investigational new drug; POC=Proof of concept;&#160;&#160;&#169; 2024 Scholar Rock, Inc. All
            rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide28.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;&#160;Appendix&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide29.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;29&#160;&#160;Proven Expertise in Anti-Latent TFGB &amp; Antimyostatin Inhibition&#160;&#160;*
            Contingent upon receipt of regulatory approval.&#160;&#160;IND=Investigational new drug; SMA=Spinal muscular atrophy; LTBP1=Latent transforming growth factor beta binding protein 1; LTBP3=Latent transforming growth factor beta binding protein 3;
            TGF&#946;-1=Transforming growth factor beta-1.&#160;&#160;1.Pirruccello-Straub M et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Reports 2017;8:2922; 2. Welsh BT et al. Preclinical safety assessment and
            toxicokinetics of apitegromab, an antibody targeting proforms of myostatin for the treatment of muscle-atrophying disease. Int J Tox 2021;40(4):322-336; 3. Barrett D et al. A randomized phase 1 safety, pharmacokinetic and pharmacodynamic study
            of a novel myostatin inhibitor apitegromab (SRK-015): A potential treatment for spinal muscular atrophy. Adv Ther 2021;38:3203-3222.&#160;&#160;Anti-Latent TGF&#946;-1&#160;&#160;Inhibition&#160;&#160;Antimyostatin Inhibition&#160;&#160;Antibody discovery technology and deep structural
            insights&#160;&#160;FOUNDATION FOR SUCCESS&#160;&#160;SRK-439 in Obesity&#160;&#160;Novel highly selective antimyostatin to preserve lean muscle &amp; avoid undesirable off-target effects1-3&#160;&#160;IND-enabling studies in 2024&#160;&#160;File IND in 2025&#160;&#160;Apitegromab in SMA&#160;&#160;In Ph 3 with
            potential to be first muscle-targeted treatment to advance the standard of care&#160;&#160;SAPPHIRE data in Q4 2024&#160;&#160;Commercial launch 2025*&#160;&#160;SRK-181 in Immuno-oncology&#160;&#160;Recent for SRK-181 data supports proof of concept and validates scientific
            hypothesis of selective targeting&#160;&#160;Fibrosis&#160;&#160;Selective context-dependent (LTBP1 &amp; LTBP3) anti-latent TGF&#946;-1&#160;&#160;NEXT HORIZON&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide30.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;-10&#160;&#160;-5&#160;&#160;0&#160;&#160;5&#160;&#160;10&#160;&#160;-60&#160;&#160;-40&#160;&#160;-20&#160;&#160;0&#160;&#160;20&#160;&#160;40&#160;&#160;60&#160;&#160;30&#160;&#160;SRK-439 Maintained Lean Mass
            When Combined with GLP-1 RA Therapy&#8224;&#160;&#160;ANOVA=Analysis of variance; GLP-1 RA=Glucagon-like peptide-1 receptor agonist; IgG=Immunoglobulin G; qNMR=Quantitative nuclear magnetic resonance.&#160;&#160;&#8224; In Mouse Diet Induced Obesity (DIO) Model.&#160;&#160;Figure shows
            the effects of increasing doses of SRK-439 in combination with liraglutide on lean mass (left panel) and fat mass (right panel) in a 28-day DIO mouse model as measured by qNMR; statistical analysis was done using one-way ANOVA (Dunnett&#8217;s
            multiple comparison test).&#160;&#160;O B E S I T Y&#160;&#160;Improved Fat Mass Loss vs GLP-1 RA Alone&#160;&#160;Increased Lean Mass Gain vs GLP-1 RA Alone&#160;&#160;% Change Fat Mass from Baseline (qNMR)&#160;&#160;% Change Lean Mass from Baseline (qNMR)&#160;&#160;%
            Change&#160;&#160;IgG&#160;&#160;0.3&#160;&#160;1&#160;&#160;3&#160;&#160;SRK-439&#160;&#160;IgG&#160;&#160;0.06 mg/kg Lira&#160;&#160;% Change&#160;&#160;IgG&#160;&#160;0.3&#160;&#160;1&#160;&#160;3&#160;&#160;SRK-439&#160;&#160;IgG&#160;&#160;0.06 mg/kg Lira&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;&#160;****&#160;&#160;****&#160;&#160;****&#160;&#160;One-way ANOVA&#160;&#160;* P &lt; 0.05&#160;&#160;** P &lt; 0.005&#160;&#160;*** P &lt;
            0.0005&#160;&#160;**** P &lt; 0.0001&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide31.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181: Targeting Latent TGFB1 to Overcome Immunotherapy
            Resistance&#160;&#160;PD-1=Programmed cell death ligand 1; TGF&#946;=Transforming growth factor-beta; ccRCC=Clear cell renal cell carcinoma&#160;&#160;1.Sumanta Kumar Pal et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell
            carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. The Lancet, Volume 402, Issue 10397, 2023, Pages 185-195,
            https://doi.org/10.1016/S0140-6736(23)00922-4&#160;&#160;S R K - 181 &#160;&#160;Enrollment completed December 2023&#160;&#160;NEXT&#160;&#160;STEPS&#160;&#160;Present ongoing emerging data at future medical meetings&#160;&#160;Conduct an end of Phase 1 meeting with regulatory authorities to inform next
            steps&#160;&#160;Differentiation&#160;&#160;Monoclonal antibody selectively targeting latent and context-independent binding to TGF&#946;1&#160;&#160;Novel and highly selective inhibition of&#160;&#160;TGF&#946;-1 targeting latent form&#160;&#160;Offers potential to avoid toxicity and dose-limiting
            challenges of non-selective TGF&#946; inhibition approaches&#160;&#160;Ph1 DRAGON Demonstrated Proof- of-Concept in ccRCC patients&#160;&#160;Showed objective, durable clinical responses above&#160;&#160;what is expected from continuing PD-1 alone1&#160;&#160;Biomarker data supports
            proof-of-mechanism in multiple tumor types&#160;&#160;31&#160;&#160;PD-1/PD-L1)&#160;&#160;&#169; 2024 Scholar Rock, Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" class="slide">
      <div style="position: relative; left: 0px; top: 0px;" class="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/92bd42ab5810bba941035bfcf0b22022-a53878319ex99_1slide32.jpg"></div>
      </div>
      <div style="text-align: center;" class="slideText">
        <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;32&#160;&#160;Promising Anti-tumor Activity in Heavily Pretreated ccRCC Patients;&#160;&#160;Biomarker
            Data Supports Proof of Mechanism Across Multiple Tumor Types&#160;&#160;ccRCC=Clear cell renal cell carcinoma&#160;&#160;Data cutoff August 29, 2023&#160;&#160;CD8 Stain &#8211; Melanoma&#160;&#160;Pre-Treatment&#160;&#160;Continued Tolerability &amp;&#160;&#160;Promising Anti-Tumor Activity in ccRCC
            Patients*&#160;&#160;Post-Treatment&#160;&#160;Best Response in Target Lesions&#160;&#160;100&#160;&#160;80&#160;&#160;60&#160;&#160;40&#160;&#160;20&#160;&#160;0&#160;&#160;-20&#160;&#160;-40&#160;&#160;-60&#160;&#160;-80&#160;&#160;-100&#160;&#160;Percent Change from Baseline&#160;&#160;Pt #6&#160;&#160;Pt #3&#160;&#160;Pt #5&#160;&#160;Pt #4&#160;&#160;Pt #1&#160;&#160;Pt #2&#160;&#160;Change in Tumor Volume Over
            Time&#160;&#160;100&#160;&#160;80&#160;&#160;60&#160;&#160;40&#160;&#160;20&#160;&#160;0&#160;&#160;-20&#160;&#160;Percent Change from Baseline&#160;&#160;-40&#160;&#160;-60&#160;&#160;-80&#160;&#160;-100&#160;&#160;0&#160;&#160;2 4 6 8 10 12 14&#160;&#160;Months on SRK-181 + Pembrolizumab Treatment&#160;&#160;Pt #1&#160;&#160;Pt #2&#160;&#160;Pt #4&#160;&#160;Pt #5&#160;&#160;Pt #3&#160;&#160;Pt #6&#160;&#160;S R K - 181 &#160;&#160;*28 patients&#160;&#160;&#169; 2024 Scholar Rock,
            Inc. All rights reserved.&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    <font style="font-weight: bold;"> </font></div>
</div>
</html>
<div><a name="a53878319ex99_2.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<div bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.2</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: left;">
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Scholar Rock Provides Corporate Update and Highlights Priorities for 2024</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to treat spinal muscular atrophy (SMA) and cardiometabolic
              disorders</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Completed enrollment for apitegromab pivotal Phase 3 SAPPHIRE trial in patients with SMA; topline data anticipated in 4Q 2024</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Apitegromab Phase 2 proof-of-concept trial in obesity expected to commence in mid-2024</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Presenting new preclinical data on SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity, at Keystone Symposia in February</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Scholar Rock reports year-end cash and cash equivalents of approximately $280 million</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 1:30 p.m. PT (4:30 p.m. ET)</i> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--January 4, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious
            diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024. </p>
          <p> &#8220;We were pleased with our progress in 2023 as we advanced our industry leading antimyostatin pipeline with apitegromab and SRK-439 and have great momentum heading into 2024. With enrollment completed for our Phase 3 SAPPHIRE trial for
            patients with spinal muscular atrophy, we expect topline data in Q4 this year,&#8221; said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock. &#8220;Additionally, we are thrilled with the planned initiation in mid-2024 of an
            apitegromab Phase 2 proof-of-concept trial in patients with obesity and on GLP-1 therapies that aims to establish the importance of selective, safe myostatin inhibition to preserve lean muscle mass as part of healthy weight loss.&#8221; </p>
          <p> <b>2024 Priorities:</b> </p>
          <p> <b><u>SPINAL MUSCULAR ATROPHY</u></b> </p>
          <p> <b>Apitegromab </b>is an investigational, fully human monoclonal antibody that inhibits myostatin activation by selectively binding the pro- and latent forms of myostatin in skeletal muscle and is being developed as a potential first
            muscle-targeted therapy for the treatment of SMA. Apitegromab is the only muscle-targeted therapy to show clinical proof-of-concept in SMA. </p>
          <ul style="list-style-type: disc;">
            <li> <b>Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024</b>. SAPPHIRE is a randomized, double-blind, placebo-controlled clinical trial evaluating apitegromab in patients with nonambulatory Types 2 and 3 SMA on
              either nusinersen or risdiplam. If the trial is successful and apitegromab is approved, the Company expects to initiate a commercial product launch in 2025. </li>
            <li> <b>Continue to progress the ONYX long-term extension study for patients from both the TOPAZ and SAPPHIRE studies.</b> </li>
          </ul>
          <p> <b><u>CARDIOMETABOLIC DISORDERS</u></b> </p>
          <p> <b>SRK-439 </b>is a novel, preclinical, investigational myostatin inhibitor that has high in vitro affinity for pro- and latent myostatin and maintains myostatin specificity (i.e., no GDF11 or Activin-A binding), and is initially being
            developed for the treatment of obesity. </p>
          <ul style="list-style-type: disc;">
            <li> <b>Initiating a Phase 2 proof-of-concept trial with apitegromab in combination with a GLP-1 receptor agonist (GLP-1 RA) in obesity in mid-2024.</b> As part of the Company&#8217;s strategy to advance the development of SRK-439, it plans to
              initiate a Phase 2 proof-of-concept trial with apitegromab in combination with a GLP-1 RA, subject to IND clearance. Data from the clinical trial are expected in mid-2025 and will be used to guide clinical development of SRK-439. The Company
              plans to file an IND for SRK-439 for the treatment of obesity in 2025. </li>
            <li> <b>Presenting preclinical SRK-439 data in a poster presentation at Keystone Symposia </b>at the<b> </b><i>Obesity: Causes and Consequences</i> meeting on February 5, 2024, in Vancouver, BC, Canada. </li>
          </ul>
          <p> <b>2023 Highlights:</b> </p>
          <ul style="list-style-type: disc;">
            <li> Completed enrollment of apitegromab pivotal Phase 3 SAPPHIRE trial. </li>
            <li> Presented TOPAZ 36-month extension trial data at the Cure SMA Research &amp; Clinical Care Meeting in June, and at the 28<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual Congress of the World Muscle Society in October, which showed long-term substantial and sustained
              improvements in motor function and patient-reported outcome measures in patients with nonambulatory Types 2 and 3 SMA receiving survival motor neuron (SMN) therapy. </li>
            <li> Initiated the ONYX trial, a long-term extension study for patients from both the TOPAZ and SAPPHIRE studies, which remains ongoing. </li>
            <li> Announced plans to expand into cardiometabolic disorders with SRK-439, starting with a Phase 2 proof-of-concept trial evaluating apitegromab in obesity to inform development of SRK-439. </li>
            <li> Presented SRK-181 Phase 1 DRAGON trial clinical and biomarker data at the SITC 38<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual Meeting, which showed favorable tolerability and promising anti-tumor activity in heavily pretreated patients with clear cell renal cell
              carcinoma (ccRCC) resistant to anti-PD-1. The Company believes these data support proof-of-concept and completed enrollment of the DRAGON trial in December. The Company will provide additional clinical data updates as they become available in
              2024. </li>
            <li> Completed an equity financing of $98 million in October. As of December 31, 2023, Scholar Rock reported cash, cash equivalents, and marketable securities of approximately $280 million, which is projected to fund the Company&#8217;s operations
              into the second half of 2025. </li>
          </ul>
          <p> &#8220;We are excited to enter 2024 with several important near-term milestones ahead of us. As the leader in selective myostatin inhibition, we believe we are well positioned to deliver significant value to patients living with spinal muscular
            atrophy and the millions of people suffering from the wide array of health challenges stemming from cardiometabolic and obesity disorders. We are highly encouraged by our potential to advance the standard of care where muscle-targeted therapies
            can play a role in addressing unmet patient needs,&#8221; said Ted Myles, Chief Operating Officer and Chief Financial Officer. </p>
          <p> <b>J.P. Morgan Healthcare Conference Presentation and Webcast</b> </p>
          <p> Scholar Rock management will highlight these updates in a corporate presentation at the 42<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m. ET). A live webcast of the presentation
            may be accessed by visiting the Investors &amp; Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company&#8217;s website for approximately 90 days following the
            presentation. </p>
          <p> <b>About Scholar Rock</b> </p>
          <p> Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta
            (TGF&#946;) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the
            past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a
            transformational role. </p>
          <p> Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application
            of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through
            traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. </p>
          <p> <b>Availability of Other Information About Scholar Rock</b> </p>
          <p> Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange
            Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material
            information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any
            filing under the Securities Act of 1933, as amended. </p>
          <p> Scholar Rock<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of Scholar Rock, Inc. </p>
          <p> <b>Forward-Looking Statements</b> </p>
          <p> This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock&#8217;s future expectations, plans and prospects,
            including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress, results and timing of its clinical trials for apitegromab and SRK-181 and its preclinical programs, including SRK-439, regulatory feedback
            including with respect to the IND submitted in connection with the planned Phase 2 trial of SRK-439 in combination with GLP-1 RAs in obesity, and indication selection and development timing, including the therapeutic potential, clinical
            benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, its expected cash and cash equivalents as of December 31, 2023 and cash runway, expectations
            regarding the achievement of important milestones, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and
            proprietary platform. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are
            intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to
            differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2
            clinical trial of apitegromab, or Part A or Part B of the Phase 1 clinical trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product
            candidates, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA or Part B of the Phase 1 clinical trial of SRK-181; Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to
            identify and develop product candidates on their expected timelines; the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials; information provided or decisions made by regulatory authorities; competition
            from third parties that are developing products for similar uses; Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property; Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates
            including, without limitation, to supply any clinical trials; Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and
            new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Quarterly Report
            on Form 10-Q for the quarter ended September 30, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking
            statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no
            duty to update this information unless required by law. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Investors &amp; Media </b><br>
            Rushmie Nofsinger <br>
            Scholar Rock <br>
            rnofsinger@scholarrock.com<br>
            ir@scholarrock.com<br>
            857-259-5573 </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: left;"><font style="font-weight: bold;"> <br>
    </font></div>
</div>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9856\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
